SEC Tracker
Get the app

Biovie BIVI

Biovie FY 2023: net loss $50.3M; diluted EPS −$1.55

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Biovie reported for the year ended Jun 30, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$50.3MAgainst −$26.1M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS−$1.55Against −$1.06 in FY 202210-K income statement, on EDGAR
  3. Cash and cash equivalents$19.5M+4% from $18.6M in FY 202210-K balance sheet, on EDGAR
  4. Cash from operations−$40.3MAgainst −$19.0M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Biovie files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. Talphera TLPH public float $8M, Jun 30, 2025
  3. Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
  4. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  5. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025